Research Library
Cagrilintide research
7 articles to explore, with links to 10 original sources.
About Cagrilintide
Cagrilintide is an amylin analogue used in research on metabolic receptor signaling.
Understand the science
How REDEFINE 1 researchers studied blood pressure
Cagrilintide is an investigational amylin-based peptide studied alone and as part of CagriSema with semaglutide. An analysis published in December 2025 examined blood pressure readings collected in the REDEFINE 1 weight-management trial.
3 sources (2023–2026)
What frozen receptor images show about cagrilintide
Cagrilintide is a long-acting peptide based on amylin, a hormone associated with signals after eating. For the specific question of how the peptide sits in its receptors, the older direct evidence comes from a 2025 study that visualized cagrilintide bound to several versions of the receptor family.
1 source (2025)
Explore study findings
Why the four arms of REDEFINE 1 mattered for cagrilintide
Cagrilintide is an investigational long-acting amylin-based peptide. The older primary REDEFINE 1 report matters for the specific question of cagrilintide alone because the large weight-management trial included a separate cagrilintide arm alongside the fixed combination.
3 sources (2025, 2026)
Check methods and identity
The trials designed to test cagrilintide on its own
Cagrilintide is an investigational, long-acting peptide that activates receptors for amylin and calcitonin. It is often discussed alongside semaglutide because they are being studied together as CagriSema.
3 sources (2025, 2026)
Interpret the evidence
Why REIMAGINE 2 compared cagrilintide with semaglutide
Cagrilintide is an investigational long-acting peptide modeled on amylin. Semaglutide acts on the GLP-1 receptor. REIMAGINE 2 studied the two peptides alone and together in people with type 2 diabetes and overweight or obesity.
2 sources (2025, 2026)
What a cagrilintide combination changed in a basal insulin trial
Cagrilintide is an investigational peptide designed to act like the hormone amylin for longer. In the 2026 REIMAGINE 3 study, researchers asked what changed when the cagrilintide–semaglutide combination, called CagriSema, was added to basal insulin in adults with type 2 diabetes.
1 source (2026)
What the Japan and Taiwan CagriSema trial adds to the evidence
Cagrilintide is a long-acting investigational amylin-based peptide. CagriSema pairs it with the GLP-1 receptor agonist semaglutide. In REDEFINE 5, researchers examined whether the combination produced a different weight change from semaglutide alone in adults studied in Japan and Taiwan.
1 source (2026)
